Top

Journal of Cancer Survivorship

Published in:

01-02-2020

Association between polypharmacy and health-related quality of life among cancer survivors in the United States

Authors: Zachary R. Babcock, Stephen J. Kogut, Ami Vyas

Published in: Journal of Cancer Survivorship | Issue 1/2020

Abstract

Purpose

Polypharmacy (PP) is present in many cancer survivors and may lead to lower health-related quality of life (HRQoL). The study’s objective was to evaluate the association between PP and HRQoL among cancer survivors in the US.

Methods

A cross-sectional analysis of the Medical Expenditure Panel Survey (MEPS) was conducted. Our analytic sample included all adult patients with cancer, during even years 2008–2014. PP was defined as reported use of five or more unique therapeutic classes of prescription medications. The MEPS measured HRQoL using the Short Form 12-Item Health Survey Version 2 (SF-12v2) physical component summary (PCS) and mental component summary (MCS) scores. Ordinary least squares regressions were used to assess associations between PP and HRQoL controlling for demographic, socioeconomic, and clinical factors.

Results

PP was prevalent among 44.4% of 10.1 million cancer survivors per calendar year (on average) for years 2008, 2010, 2012, and 2014. The mean adjusted PCS score for cancer survivors with PP was 35.8 points, which was significantly lower compared with cancer survivors without PP (39.5) by 3.7 points (p value < .0001). Conversely, the mean adjusted MCS scores were not significantly lower in cancer survivors with PP compared with cancer survivors without PP (44.9 versus 45.4, p value = 0.3145).

Conclusions

PP was prevalent in 44.4% of cancer survivors and was associated with significantly poorer physical HRQoL than reported in their counterparts without PP.

Implications for Cancer Survivors

PP should be examined closely among cancer survivors because of increased association with poorer physical HRQoL.

Available only for authorised users

NCI Dictionary of Cancer Terms was originally produced by the National Cancer Institute. Available Online: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/survivorship. Accessed May 31, 2019

Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev. 2012;21(11):2108–17. https://doi.org/10.1158/1055-9965.EPI-12-0740.CrossRef

Cancer treatment & survivorship facts & figures 2016–2017 is accompanied by “Cancer Treatment and Survivorship Statistics, 2016,” a scientific paper published in the American Cancer Society Journal, CA: A Cancer Journal for Clinicians.

Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors–a systematic review of quantitative studies. Psychooncology. 2013;22(1):1–11. https://doi.org/10.1002/pon.3022 Review.CrossRefPubMed

Rowland JH, Bellizzi KM. Cancer survivorship issues: life after treatment and implications for an aging population. J Clin Oncol. 2014;32(24):2662–8. https://doi.org/10.1200/JCO.2014.55.8361 Review.CrossRefPubMedPubMedCentral

Murphy CC, Fulling HM, Alvarez CA, et al. Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer. 2018;1:124(13). https://doi.org/10.1002/cncr.31389.CrossRef

Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29. https://doi.org/10.2147/CLEP.S47150 Review.CrossRefPubMedPubMedCentral

Loh KY, Ng T, Lee CP, Ng R, Chan A. Medication use by early-stage breast cancer survivors: a 1-year longitudinal study. Support Care Cancer. 2016;24(4):1639–47. https://doi.org/10.1007/s00520-015-2950-z.CrossRefPubMed

Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507–22. https://doi.org/10.1634/theoncologist.2009-0290 Review.CrossRefPubMedPubMedCentral

10.

van Leeuwen RWF, Brundel DHS, Neef C, van Gelder T, Mathijssen RH, Burger DM, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5):1071–8. https://doi.org/10.1038/bjc.2013.48.CrossRefPubMedPubMedCentral

11.

van Leeuwen RWF, Jansman FGA, Van den Bemt, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 2015;26(5):992–997. https://doi.org/10.1093/annonc/mdv029.CrossRef

12.

Aziz NM. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol. 2007;46(4):417–32 Review.CrossRef

13.

National Cancer Institute (NCI). Late effects of treatment for childhood cancer (PDQ®)–patient version was originally published by the National Cancer Institute. Available Online: https://www.cancer.gov/types/childhood-cancers/late-effects-pdq. Accessed May 31, 2019.

14.

Lu R, Krull KR, Leisenring W, et al. Pain in long-term adult survivors of childhood cancers and their siblings: a report from the childhood cancer survivor study. Pain. 2011;152(11):2616–24. https://doi.org/10.1016/j.pain.2011.08.006.CrossRefPubMedPubMedCentral

15.

Limper AH. Chemotherapy-induced lung disease. Clin Chest Med. 2004;25(1):53–64. Review. https://doi.org/10.1016/S0272-5231(03)00123-0.CrossRefPubMed

16.

Meraya AM, Dwibedi N, Sambamoorthi U. Polypharmacy and health-related quality of life among US adults with arthritis, medical expenditure panel survey, 2010-2012. Prev Chronic Dis. 2016;13:E132. https://doi.org/10.5888/pcd13.160092.CrossRefPubMedPubMedCentral

17.

Medical expenditure panel survey; agency for healthcare research and quality. available: https://meps.ahrq.gov/mepsweb/. Accessed May 31, 2019

18.

Agency for healthcare research and quality. Medical expenditure panel survey, HC-138: 2010 Full Year Consolidated Data File; 2012. https://meps.ahrq.gov/data_stats/download_data/pufs/h138/h138doc.pdf. Accessed May 31, 2019.

19.

Machlin S, Soni A, Fang Z. Understanding and analyzing MEPS household component medical condition data. Available Online: https://meps.ahrq.gov/survey_comp/MEPS_condition_data.shtml. Accessed May 31, 2019.

20.

Wang SY, Hsu SH, Gross CP, Sanft T, Davidoff AJ, Ma X, et al. Association between time since cancer diagnosis and health-related quality of life: a population-level analysis. Value Health. 2016;19(5):631–8. https://doi.org/10.1016/j.jval.2016.02.010.CrossRefPubMedPubMedCentral

21.

Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care. 2014;31(2):126–31. https://doi.org/10.1177/1049909113476132.CrossRefPubMed

22.

Cheak-Zamora NC, Wyrwich KW, McBride TD. Reliability and validity of the SF12-v2 in the medical expenditure panel survey. Qual Life Res. 2009;18(6):727–35. https://doi.org/10.1007/s11136-009-9483-1.CrossRefPubMed

23.

Park J, Look KA. Relationship between objective financial burden and the health-related quality of life and mental health of patients with cancer. J Oncol Pract. 2018;14(2):e113–21. https://doi.org/10.1200/JOP.2017.027136.CrossRefPubMed

24.

Bhandari NR, Kathe N, Hayes C, Payakachat N. Reliability and validity of SF-12v2 among adults with self-reported cancer. Res Social Adm Pharm. 2018;14(11):1080–4. https://doi.org/10.1016/j.sapharm.2018.01.007.CrossRefPubMed

25.

Masnoon N, Shakib S, Kalisch-Ellett L, Caughry GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2 Review.CrossRefPubMedPubMedCentral

26.

Agency for healthcare research and quality. Medical expenditure panel survey, HC-135A: 2010 Prescribed Medicines; 2012. https://meps.ahrq.gov/data_stats/download_data/pufs/h135a/h135adoc.pdf. Accessed May 31, 2019.

27.

Vyas A, Babcock Z, Kogut S. Impact of depression treatment on health-related quality of life among adults with cancer and depression: a population-level analysis. J Cancer Surviv. 2017;11(5):624–33. https://doi.org/10.1007/s11764-017-0635-y.CrossRefPubMed

28.

Yuan Y. Multiple imputation using SAS software. J Stat Software. 2011;45(6):ISSN: 1548–7660 (Online).CrossRef

29.

Smith C, Kosten S. Multiple imputation: a statistical programming story. PharmaSUG 2017 Paper SP01. Available Online: https://pharmasug.org/proceedings/2017/SP/PharmaSUG-2017-SP01.pdf. Accessed May 31, 2019.

30.

MEPS Topics: Medical conditions file. Medical Expenditure Panel Survey; Agency for Healthcare Research and Quality. Available: https://meps.ahrq.gov/mepsweb/data_stats/MEPS_topics.jsp?topicid=32Z-1. Accessed May 31, 2019.

31.

Kleinbaum DG, Klein M. Logistic regression: a self-learning text. 3rd ed. New York: Springer; 2010.CrossRef

32.

Vyas A, Pan X, Sambamoorthi U. Chronic condition clusters and polypharmacy among adults. Int J Family Med. 2012;2012:193168. https://doi.org/10.1155/2012/193168.CrossRefPubMedPubMedCentral

33.

Turner JP, Jamsen KS, Shakib S, Singhal N, Prowse R, Bell JS. Polypharmacy cut-points in older people with cancer: how many medications are too many? Support Care Cancer. 2016;24(4):1831–40. https://doi.org/10.1007/s00520-015-2970-8.CrossRefPubMed

34.

Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7(5):346–53. https://doi.org/10.1016/j.jgo.2016.07.010 Review.CrossRefPubMedPubMedCentral

35.

Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol. 2014;5(3):307–14. https://doi.org/10.1016/j.jgo.2014.04.002.CrossRefPubMedPubMedCentral

36.

Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12(13):1249–57. https://doi.org/10.1016/S1470-2045(11)70040-7 Review.CrossRefPubMed

37.

Cheung AS, de Rooy C, Hoermann R, Joon DL, Zajac JD, Grossmann M. Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. Clin Endocrinol. 2017;86(3):388–94. https://doi.org/10.1111/cen.13249.CrossRef

38.

Roydhouse JK, Gutman R, Keating NL, Mor V, Wilson IB. Proxy and patient reports of health-related quality of life in a national cancer survey. Health Qual Life Outcomes. 2018;16(1):6. https://doi.org/10.1186/s12955-017-0823-5.CrossRefPubMedPubMedCentral

39.

Ware J Jr, Gandek B, Sinclair SJ, et al. Measuring and improving health outcomes: an SF-36 primer for the Medicare health outcomes survey. Health assessment lab and QualityMetric incorporated, Waltham; 2004.

40.

LeMasters T, Madhavan S, Sambamoorthi U, Kurian S. A population-based study comparing HRQoL among breast, prostate, and colorectal cancer survivors to propensity score matched controls, by cancer type, and gender. Psychooncology. 2013;22(10):2270–82. https://doi.org/10.1002/pon.3288.CrossRefPubMedPubMedCentral

41.

Greenwald HP, McCorkle R, Baumgartner K, Carolyn G, Neale AV. Quality of life and disparities among long-term cervical cancer survivors. J Cancer Surviv. 2014;8:419–26. https://doi.org/10.1007/s11764-014-0352-8.CrossRefPubMed

42.

Corcoran ME. Polypharmacy in the older patient with cancer. Cancer Control. 1997;4(5):419–28.CrossRef

Title: Association between polypharmacy and health-related quality of life among cancer survivors in the United States
Authors: Zachary R. Babcock
Stephen J. Kogut
Ami Vyas
Publication date: 01-02-2020
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 1/2020
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-019-00837-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 1/2020

Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors

Correction to: influenza vaccination in caregivers of childhood cancer survivors

Process evaluation of a tailored work-related support intervention for patients diagnosed with gastrointestinal cancer

Innovations in cancer survivorship care: “Lessons from the Clinic” special section

Clinical placement program in cancer survivorship for primary care providers 2017–2019

Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control

Keynote webinar | Spotlight on antibody–drug conjugates in cancer